PDCD1 and Merkel cell skin cancer: Three types of immune checkpoint inhibitors are currently being applied on MCC patients: pembrolizumab and nivolumab, antibodies against programmed cell death-1 (PD-1), avelumab, an antibody against the ligand of PD-1, PD-L1, and the CTLA-4 antibody ipilimumab.